Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K12 | Q12852 | 12/20 | 0.36 |
| ▸ | DLK1 | P80370 | 2/20 | 0.36 |
| ▸ | PLAT | P00750 | 1/20 | 0.35 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.34 |
| ▸ | CRACR2A | Q9BSW2 | 3/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25225550 | 1.00 | MAP3K12 (0.36) | MAP3K12DLK1PLATKCNN4CRACR2A | |
| SCHEMBL25227346 | 0.92 | MAP3K12 (0.35) | MAP3K12DLK1PLATKCNN4CRACR2A | |
| SCHEMBL25270744 | 0.92 | MAP3K12 (0.35) | MAP3K12DLK1PLATKCNN4CRACR2A | |
| SCHEMBL25270745 | 0.92 | MAP3K12 (0.35) | MAP3K12DLK1PLATKCNN4CRACR2A | |
| SCHEMBL25230154 | 0.92 | MAP3K12 (0.40) | MAP3K12DLK1PLATCRACR2AGRIN1 | |
| SCHEMBL6887363 | 0.83 | MAP3K12 (0.44) | MAP3K12DLK1CRACR2A | |
| SCHEMBL25226539 | 0.82 | IDH1 (0.42) | MAP3K12 | |
| SCHEMBL25277885 | 0.82 | IDH1 (0.42) | MAP3K12 | |
| SCHEMBL31575545 | 0.82 | MAP3K12 (0.48) | MAP3K12DLK1 | |
| SCHEMBL25272259 | 0.82 | IDH1 (0.42) | MAP3K12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240398781-A1 | SPIROCYCLIC CYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | CONVELO THERAPEUTICS, INC. | 2024-12-05 | — | — | US | disclosed |
| EP-4436975-A1 | SPIROCYCLIC CYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | Genentech, Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| CN-118696050-A | Spirocyclic cyclic modulators of cholesterol biosynthesis and their use for promoting remyelination | 基因泰克公司 | 2024-09-24 | — | — | CN | disclosed |
| WO-2023097233-A1 | SPIROCYCLIC CYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | GENENTECH, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240398781-A1 | SPIROCYCLIC CYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | MAG, PMP22, NR1H2 | MAP3K12 2154/4885DLK1 792/4885PLAT 4282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.